Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Rises By 314.4%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 11,113 shares, a growth of 314.4% from the April 30th total of 2,682 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 14,125 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Santen Pharmaceutical Stock Performance

Shares of OTCMKTS SNPHY opened at $12.03 on Friday. The stock has a 50 day moving average price of $11.25 and a 200 day moving average price of $10.86. Santen Pharmaceutical has a 52 week low of $9.22 and a 52 week high of $12.68. The stock has a market capitalization of $3.88 billion and a PE ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.